Triple drug combo aims to reverse heart scarring in stiff heart failure
NCT ID NCT06655480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a three-drug combination (SGLT2 inhibitor, ARNI, and MRA) can improve heart structure, function, and symptoms in 50 people with advanced HFpEF, a type of heart failure where the heart is stiff but pumps normally. Participants will receive either the triple therapy or standard care for 52 weeks. The goal is to see if the combination reduces heart scarring and improves exercise ability and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HFPEF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
RECRUITINGMoscow, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hormone therapy may shield menopausal hearts and brains — a trial puts it to the test
- Heart failure clues: study tracks 500 patients for 3 years
- New contrast agent could mean lower doses for heart MRI
- Smartphone coaching aims to reverse heart damage from high blood pressure
- Blood pressure drug may shield hearts during breast cancer radiation
- Veterans' heart failure study tests simple knee exercise fix